Frontiers in Pharmacology | Drugs Outcomes Research and Policies

Original Research

Published on 05 Jul 2024

A point prevalence survey and monitoring indicator research on the second batch of national key monitoring and rational use drugs

in Drugs Outcomes Research and Policies

Li Tang
Hongmei Liu
Shasha Wu
Jing Liu
Xiaoyu Jiang
Yuanyuan Fu
Na Tao
Yong He

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1416010

1,020 views

Original Research

Published on 02 Jul 2024

Patient preferences for generic substitution policies: a discrete choice experiment in China

in Drugs Outcomes Research and Policies

Lingli Zhang
Dashuang Li
Xin Li
Jianzhou Yan

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1400156

1,844 views
1 citation

Original Research

Published on 28 Jun 2024

Development and validation of the BMQ-AIR©: a screening tool for assessing patients’ treatment beliefs about switching to anti-inflammatory reliever (AIR) therapy

in Drugs Outcomes Research and Policies

Holly Foot
Amy Hai Yan Chan
Rob Horne

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1351851

1,307 views

Original Research

Published on 27 Jun 2024

Does China’s national volume-based drug procurement policy promote or hinder pharmaceutical innovation?

in Drugs Outcomes Research and Policies

Xiujuan Li
Jiachun Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1392239

5,135 views
6 citations

Original Research

Published on 26 Jun 2024

Physicians’ perceptions and awareness of adverse effects of proton pump inhibitors and impact on prescribing patterns

in Drugs Outcomes Research and Policies

Abdelmoneim Awad
Abdulaziz Al-Tunaib
Sarah Al-Saraf

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1383698

2,323 views
2 citations

Original Research

Published on 24 Jun 2024

Unraveling elements of value-based pricing from a pharmaceutical industry’s perspective: a scoping review

in Drugs Outcomes Research and Policies

Aniek Dane
Carin Uyl-de Groot
Hugo van der Kuy

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1298923

4,357 views

Original Research

Published on 20 Jun 2024

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer

in Drugs Outcomes Research and Policies

Gengwei Huo
Ying Song
Wei Liu
Hua Guo
Peng Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1391896

3,081 views
3 citations

Original Research

Published on 19 Jun 2024

Implementation of risk-based lipid-lowering therapies in older (age ≥ 65 years) and very-old adults (age ≥ 75 years) with ischemic heart disease in the greater Salzburg region

in Drugs Outcomes Research and Policies

Kristen Kopp
Lukas J. Motloch
Bernhard Wernly
Alexander E. Berezin
Victoria Maringgele
Anna Dieplinger
Uta C. Hoppe
Michael Lichtenauer

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1357334

1,643 views

Original Research

Published on 19 Jun 2024

Understanding patient demand for and use of antibiotics for upper respiratory tract infection: A qualitative application of the Necessity-Concerns Framework in Saudi Arabia

in Drugs Outcomes Research and Policies

Nouf Almeshal
Holly Foot
Amy Louise Clarke
Amy Hai Yan Chan
Rob Horne

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1399698

3,167 views

Original Research

Published on 18 Jun 2024

Development and validation of a drug clinical trial participation feelings questionnaire for cancer patients

in Drugs Outcomes Research and Policies

Chaowei Guo
Shujun Xing
Guo Zhao
Dawei Wu
Ning Li
Shuhang Wang
Ling Yu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1371811

2,053 views

Original Research

Published on 17 Jun 2024

Treatment of hypertension during pregnancy: a cohort of pregnancy episodes from the SIDIAP database, Catalonia, Spain

in Drugs Outcomes Research and Policies

Ainhoa Gomez-Lumbreras
Carles Vilaplana-Carnerero
Marta Lestón Vázquez
Cristina Vedia
Rosa Morros
Maria Giner-Soriano

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1346357

1,503 views

Original Research

Published on 14 Jun 2024

Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United States

in Drugs Outcomes Research and Policies

Ya-Ning Zhu
Meng Tang
Ke-Xin Sun
Bei Gao
Xian-Peng Shi
Peng Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1348688

2,641 views
2 citations

Original Research

Published on 14 Jun 2024

Capecitabine-associated gastrointestinal ulceration, haemorrhage, and obstruction: a pharmacovigilance analysis based on the FAERS

in Drugs Outcomes Research and Policies

Yuwei Wang
Long Meng
Xiao Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1412938

1,998 views
1 citation

Review

Published on 13 Jun 2024

Orphan drug policy analysis in China

in Drugs Outcomes Research and Policies

Meilin Liu
Yanqin Lu
Junfeng Li
Yongtao Zhang
Shanshan Zhang
Yisheng Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1278710

5,319 views
2 citations

Original Research

Published on 10 Jun 2024

Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)

in Drugs Outcomes Research and Policies

Ruibo Li
Xingyue Yuan
Xi Chen
Yili Ou
Jin Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1358592

4,637 views
3 citations

Original Research

Published on 10 Jun 2024

Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector’s and societal perspectives

in Drugs Outcomes Research and Policies

Yena Gan
Fenghao Shi
He Zhu
Huangqianyu Li
Sheng Han
Duoduo Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1256992

2,377 views